Influenza Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc

The Influenza Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Influenza Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Influenza Market.

Some of the key takeaways from the Influenza Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Influenza treatment therapies with a considerable amount of success over the years. 
• Influenza companies working in the treatment market are Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc, GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Ena Respiratory, Valenta Pharmaceuticals, Raynovent Co., Ltd, and others, are developing therapies for the Influenza treatment 

• Emerging Influenza therapies in the different phases of clinical trials are- LUNAR-FLU, naNO-Flu, UniFlu, CC-42344,GSK4382276A, CVSQIV, ALVR 106, mRNA-1073, OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others are expected to have a significant impact on the Influenza market in the coming years.   
• In July 2022, Emergex Vaccines Holding Limited has achieved the production of its universal/pandemic influenza vaccine designed for Phase I clinical trials, utilizing fully synthetic CD8+ T cell Adaptive Vaccines.
• CureVac has initiated the dosing of the initial participant in a Phase I trial for the modified influenza vaccine FLU SV mRNA, developed in partnership with GSK. This trial comes subsequent to the commencement of another Phase I study in February 2022, assessing an unmodified, multivalent influenza vaccine candidate, CVSQIV, across clinical sites in Panama. Both studies aim to present combined data upon completion.
• In June 2022, Moderna, Inc. revealed the initiation of dosing in a Phase III trial for its seasonal influenza vaccine candidate, mRNA-1010, with the initial participants receiving doses. Anticipated to enroll about 6,000 adults in Southern Hemisphere nations, this Phase III randomized, observer-blind study aims to assess the safety and immune response of mRNA-1010 compared to a licensed seasonal influenza vaccine in adults aged 18 years and above.
• In April 2022, Novavax, Inc. released preliminary findings from the Phase I/II clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC merges Novavax’s COVID-19 vaccine, NVX-CoV2373, with its quadrivalent influenza vaccine candidate. The trial confirmed the viability of formulating this combined vaccine, showing good tolerance and immune response.
• In April 2022, Osivax has announced the publication of Phase IIa results for its universal influenza vaccine candidate, OVX836, titled “Randomized, Double-Blind, Reference-Controlled, Phase IIa Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine” in the journal Frontiers in Immunology. Utilizing Osivax’s self-assembling nanoparticle technology, OVX836 focuses on an internal nucleoprotein (NP), an antigen less prone to frequent mutations compared to surface antigens of the influenza virus.
• BioNTech and Pfizer have joined forces to develop an influenza vaccine utilizing BioNTech’s mRNA platforms. In July 2022, data from the Phase II expansion study of BNT161 in participants aged 65 and older revealed initial evidence of significantly enhanced induction of strain-specific CD4+ and CD8+ responses. The geometric mean fold rise (GMFR) was notably higher compared to the control quadrivalent influenza vaccine for both CD4+ and CD8+ strain-specific T cell responses. Encouraged by these promising T cell responses and observed seroconversion, plans are underway to commence a Phase III study for the quadrivalent modified mRNA influenza vaccine in the latter half of 2022.
• In May 2022, Blue Water Vaccines revealed a partnership with the Center for R&D in Immunobiologics, part of the Instituto Butantan, to advance BWV’s universal influenza candidate, BWV-101, in Brazil. Butantan stands as the primary flu vaccine producer in the Southern Hemisphere, responsible for manufacturing all influenza vaccine doses employed by the Brazilian Ministry of Health.

Influenza Overview

A contagious virus that affects the upper respiratory system, including the upper and lower respiratory passages, called influenza.It is caused by a broad range of influenza viruses. While some of these viruses are unique to particular species, others can infect humans.

Get a Free Sample PDF Report to know more about Influenza Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/influenza-pipeline-insight

Emerging Influenza Drugs Under Different Phases of Clinical Development Include:

• LUNAR-FLU: Arcturus Therapeutics
• naNO-Flu: Emergex Vaccines
• UniFlu: Emergent Biosolutions
• CC-42344: Cocrystal Pharma Inc
• GSK4382276A: GlaxoSmithKline
• CVSQIV: CureVac AG
• ALVR 106: AlloVir
• mRNA-1073: Moderna
• OVX836: OSIVAX
• Neumifil: Pneumagen Ltd.
• INNA-051: Ena Respiratory
• mRNA-1010: Moderna, Inc.
• XC-221: Valenta Pharmaceuticals
• ZSP1273: Raynovent Co., Ltd

Influenza Route of Administration

Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Influenza Molecule Type

Influenza Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Influenza Pipeline Therapeutics Assessment

• Influenza Assessment by Product Type
• Influenza By Stage and Product Type
• Influenza Assessment by Route of Administration
• Influenza By Stage and Route of Administration
• Influenza Assessment by Molecule Type
• Influenza by Stage and Molecule Type

DelveInsight’s Influenza Report covers around 120+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Influenza product details are provided in the report. Download the Influenza pipeline report to learn more about the emerging Influenza therapies

Some of the key companies in the Influenza Therapeutics Market include:

Key companies developing therapies for Influenza are – AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC, and others.

Influenza Pipeline Analysis:

The Influenza pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Influenza with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
• Influenza key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Influenza Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Influenza market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Influenza drugs and therapies

Influenza Pipeline Market Drivers

• Increasing awareness by government authorities, increasing clinical trials for new product development, increase in investment by leading market players are some of the important factors that are fueling the Influenza Market.

Influenza Pipeline Market Barriers

• However, longer process for novel vaccine development, high cost of vaccine development other factors are creating obstacles in the Influenza Market growth.

Scope of Influenza Pipeline Drug Insight    

• Coverage: Global
• Key Influenza Companies: Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc, GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Ena Respiratory, Valenta Pharmaceuticals, Raynovent Co., Ltd, and others
• Key Influenza Therapies: LUNAR-FLU, naNO-Flu, UniFlu, CC-42344,GSK4382276A, CVSQIV, ALVR 106, mRNA-1073, OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others
• Influenza Therapeutic Assessment: Influenza current marketed and Influenza emerging therapies
• Influenza Market Dynamics: Influenza market drivers and Influenza market barriers 

Request for Sample PDF Report for Influenza Pipeline Assessment and clinical trials

Table of Contents

1. Influenza Report Introduction

2. Influenza Executive Summary

3. Influenza Overview

4. Influenza- Analytical Perspective In-depth Commercial Assessment

5. Influenza Pipeline Therapeutics

6. Influenza Late Stage Products (Phase II/III)

7. Influenza Mid Stage Products (Phase II)

8. Influenza Early Stage Products (Phase I)

9. Influenza Preclinical Stage Products

10. Influenza Therapeutics Assessment

11. Influenza Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Influenza Key Companies

14. Influenza Key Products

15. Influenza Unmet Needs

16 . Influenza Market Drivers and Barriers

17. Influenza Future Perspectives and Conclusion

18. Influenza Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services